The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation
Open Access
- 1 November 2007
- journal article
- review article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 11 (45)
Abstract
Health Technology Assessment Volume: 11, Issue: 45, Published in November 2007Keywords
Funding Information
- Health Technology Assessment Programme (04/20/01)
This publication has 140 references indexed in Scilit:
- Molecular pathology and clinical characteristics of oligodendroglial neoplasmsAnnals of Neurology, 2005
- Chromosomal anomalies in oligodendroglial tumors are correlated with clinical featuresCancer, 2003
- Molecular markers of prognosis in astrocytic tumorsCancer, 2002
- A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade gliomaCancer, 2001
- Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy gradesGenes, Chromosomes and Cancer, 1998
- Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomasCancer, 1997
- Descriptive epidemiology of cerebral gliomas in FranceCancer, 1997
- Diagnostic discrepancies and their clinical impact in a neuropathology referral practiceCancer, 1997
- Central pathology review in clinical trials for patients with malignant glioma. A report of radiation therapy oncology group 83-02Cancer, 1995
- The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumorsCancer, 1995